Xencor | XNCR - Cash And Equivalent


Xencor reported $14.17M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
AbbVie USD 9.39B 4.16B Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
Arrowhead Research USD 201.64M 112.94M Dec/2025
AstraZeneca USD 7.56B 1.85B Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Cytokinetics USD 129.84M 7.32M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
J&J USD 21.69B 1.98B Mar/2026
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
MacroGenics USD 66.52M 9.3M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Xencor USD 14.17M 39.9M Mar/2026